Human Pharmson Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 18.03%
About Human Pharmson
Human Pharmson Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 August 2020 (Four years and five months 29 days old ). Its registered office is in Gandhi Nagar, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bharatkumar Dahyalal and Sunny Patel serve as directors at the Company.
Company Details
-
Location
Gandhi Nagar, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999GJ2020PTC115587
-
Company No.
115587
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Aug 2020
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Human Pharmson?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharatkumar Dahyalal
|
Director | 18-Aug-2020 | Current |
|
Sunny Patel
|
Director | 18-Aug-2020 | Current |
Financial Performance of Human Pharmson.
Human Pharmson Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Human Pharmson?
In 2022, Human Pharmson had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Human Pharma Labs Private LimitedBharatkumar Dahyalal and Sunny Patel are mutual person
-
Umiya Enviro Project LlpBharatkumar Dahyalal is a mutual person
-
Jayvir Organics Private Limited
Bharatkumar Dahyalal is a mutual person
-
Harra Polymers Private Limited
Sunny Patel is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Human Pharmson?
Human Pharmson has a workforce of 0 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Human Pharmson, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Human Pharmson's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.